SABS
What one share of Sab Biotherapeutics holds
Biological Products, (No Diagnostic Substances)
We are a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. Our programs are based on mechanisms of action that have achieved proof-of-concept in clinical trials in indications with significant unmet medical needs.
Sab Biotherapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.14 |
|---|---|
| Cash and investments | $0.10 |
| Book value | $2.57 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $20.45 | $7.45 | $4.71 | −$1.01 | — | $15.02 |
| 2021 | $22.27 | −$6.27 | $4.00 | −$3.28 | — | $8.86 |
| 2022 | $5.49 | −$4.31 | $0.50 | −$5.89 | — | $6.16 |
| 2023 | $0.41 | −$7.64 | $0.04 | −$4.59 | — | $6.21 |
| 2024 | $0.14 | −$3.68 | $0.04 | −$3.74 | — | $2.80 |
| 2025 | $0.00 | −$0.79 | $0.02 | −$0.75 | — | $3.18 |